Study identifier:3591IL/0079
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicenter, Randomized, Double blind, Comparative trial of intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (imipenem-cilastatin) in the treatment of hospitalised subjects with complicated skin and skin structure infections.
Skin Infection, Abscess
Phase 3
No
Meropenem, Imipenem-cilastatin
All
1000
Interventional
13 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Meropenem | Drug: Meropenem Intravenous Other Name: Merrem Drug: Meropenem Intravenous Other Name: Merrem Drug: Meropenem Intravenous Other Name: Merrem |
Active Comparator: 2 Imipenem-cilastatin | Drug: Imipenem-cilastatin Intravenous Other Name: Primaxin |